← Back to Analyst Consensus 
BOLT Buy
Bolt Biotherapeutics, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 29, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| May 28, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 13, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 15, 2025 | Lake Street | maintain | Buy → Buy | $75 | 47% |
| May 20, 2025 | Lake Street | initiate | — → Buy | $4 | 47% |
| May 13, 2025 | Stifel | maintain | Hold → Hold | $1 | 53% |
| Mar 25, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Mar 25, 2025 | Stifel | maintain | Hold → Hold | $1.25 | 53% |
| Nov 13, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| Aug 15, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| May 15, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $1 | 50% |
| May 15, 2024 | Jones Trading | downgrade | Buy → Hold | $0 | 50% |
| May 15, 2024 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| May 15, 2024 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| May 15, 2024 | Stifel | downgrade | Buy → Hold | $1.5 | 53% |
| Mar 22, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Aug 8, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Aug 3, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $8 | 44% |
| Jun 5, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| May 26, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $8 | 44% |
| May 12, 2023 | SVB Leerink | upgrade | Market Perform → Outperform | $4 | — |
| May 12, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 30, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $8 | 44% |
| Jan 24, 2023 | Morgan Stanley | maintain | — → Equal-Weight | $3 | 54% |
| Oct 4, 2022 | HC Wainwright & Co. | initiate | — → Buy | $8 | 44% |
| Aug 11, 2022 | SVB Leerink | downgrade | Outperform → Market Perform | $4 | — |
| May 17, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $5 | 54% |
| Jan 6, 2022 | Morgan Stanley | downgrade | Overweight → Equal-Weight | $11 | 54% |
| Nov 10, 2021 | SVB Leerink | maintain | — → Outperform | $33 | — |
| Aug 16, 2021 | SVB Leerink | maintain | — → Outperform | $35 | — |
| May 17, 2021 | SVB Leerink | maintain | — → Outperform | $33 | — |
| Apr 6, 2021 | SVB Leerink | maintain | — → Outperform | $37 | — |
| Mar 2, 2021 | Stifel | initiate | — → Buy | $40 | 53% |
| Mar 2, 2021 | Guggenheim | initiate | — → Buy | $42 | 52% |
| Mar 2, 2021 | Morgan Stanley | initiate | — → Overweight | $45 | 54% |
| Mar 2, 2021 | SVB Leerink | initiate | — → Outperform | $36 | — |
Price Target Trend
Apr 24, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days